Clinical trial shows retatrutide leads to significant weight loss in adults with obesity — Evidence Review
Published in The Lancet, by researchers from Eli Lilly
Researched by
— the AI search engine for science
Table of Contents
A new phase 3 clinical trial found that retatrutide, an investigational weekly injection, led to substantial weight loss and improved blood sugar control in adults with obesity and type 2 diabetes. Related studies generally confirm these results, showing that retatrutide and similar triple-agonist drugs outperform existing obesity medications in terms of weight loss, though gastrointestinal side effects are common (original study source).
- The new findings align with previous phase 2 trials and meta-analyses demonstrating superior weight loss efficacy of retatrutide compared to placebo and established GLP-1 receptor agonists, especially in adults without diabetes, although efficacy is somewhat reduced in those with type 2 diabetes 1 2 5 11 12 13.
- Several related studies highlight robust metabolic and cardiovascular benefits—including reductions in blood pressure, lipid profiles, and liver fat—supporting the broader health impacts observed in the current phase 3 trial 3 11 13.
- Safety profiles across studies are consistent, with retatrutide and similar agents associated mainly with mild-to-moderate gastrointestinal adverse events, such as nausea and diarrhea, leading to some discontinuations but few serious complications 1 2 5 12 13.
Study Overview and Key Findings
Obesity and type 2 diabetes are prevalent, chronic conditions with limited pharmacologic options for effective, sustained weight loss. While GLP-1 receptor agonists, such as semaglutide and tirzepatide, have improved outcomes, weight loss among people with type 2 diabetes often remains less robust than in those without diabetes. The recently published TRIUMPH-2 phase 3 trial investigates whether retatrutide, a triple hormone receptor agonist, can address this unmet need by targeting multiple metabolic pathways simultaneously. This multinational study is notable for its large sample size, long duration, and focus on a high-risk population with longstanding obesity and diabetes.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | Eli Lilly |
| Journal Name | The Lancet |
| Authors | Virginia Bellido, Carel W le Roux, Elif I Ekinci, Petter Bjornstad, Juan P Frias, Kathryn Giblin, Sarah Eyde, So Young Park, João Ferro, Caroline Johnson, Amanda Taylor |
| Population | Adults with obesity and type 2 diabetes |
| Sample Size | n=1152 |
| Methods | Randomized Controlled Trial (RCT) |
| Outcome | Weight loss, blood sugar control, cardiometabolic risk factors |
| Results | Participants lost up to 18.8% of starting weight with retatrutide. |
Literature Review: Related Studies
To contextualize these results, we searched the Consensus database of over 200 million research papers using targeted queries. The following search queries were used:
- retatrutide weight loss effectiveness
- weight loss drug clinical trial results
- obesity treatment comparison retatrutide Ozempic
| Topic | Key Findings |
|---|---|
| How effective is retatrutide for weight loss and metabolic outcomes? | - Retatrutide leads to substantial reductions in body weight (up to 24.2% in some trials) and improved metabolic markers in adults with obesity, with effects observed across various populations 1 2 3 5 11 12 13. - Weight loss efficacy is generally greater in adults without diabetes, but meaningful reductions are also seen in those with type 2 diabetes 2 5 12. |
| How does retatrutide compare to other weight loss drugs (e.g., semaglutide, tirzepatide)? | - Meta-analyses and head-to-head studies indicate retatrutide produces greater weight loss than semaglutide, liraglutide, and even tirzepatide in most populations, with the triple-agonist mechanism providing additional benefit 4 5 12. - The advantage is more pronounced in non-diabetic populations; those with type 2 diabetes see less, but still significant, weight reduction 5 12. |
| What are the main safety considerations and adverse events? | - Gastrointestinal side effects (nausea, diarrhea, vomiting) are the most common adverse events, typically mild to moderate and dose-dependent; discontinuation rates are higher with retatrutide and similar agents than placebo, but serious adverse events are rare 1 2 4 5 12 13. - Rates and types of adverse events are similar to other GLP-1 receptor agonists and dual agonists 2 4 13. |
| What broader health impacts (beyond weight loss) have been observed? | - Significant improvements in glycemic control, blood pressure, lipid profiles, and liver fat have been documented in multiple studies; some evidence also suggests potential benefit for other obesity-related complications 3 11 13. - The impact on long-term cardiovascular outcomes and other chronic complications is still under investigation 3 11. |
How effective is retatrutide for weight loss and metabolic outcomes?
The new TRIUMPH-2 study’s findings of substantial, dose-dependent weight loss and improved metabolic markers are consistent with previous phase 2 trials and meta-analyses. Across diverse populations, retatrutide has demonstrated significant reductions in body weight, waist circumference, and glycemic indices, with efficacy generally greater in non-diabetic individuals but still meaningful in those with type 2 diabetes.
- Multiple randomized trials and meta-analyses show retatrutide produces robust weight loss (up to 24.2% reduction), outperforming most other available obesity treatments 1 2 3 5 11 12 13.
- The magnitude of weight loss is somewhat lower in patients with type 2 diabetes compared to non-diabetic participants, but remains clinically significant 2 5 12.
- Improvements in metabolic markers, including HbA1c, fasting glucose, and blood pressure, have been consistently reported 2 3 11 13.
- The new study’s 80-week duration extends previous findings by demonstrating sustained weight loss over a longer period 1 2 13.
How does retatrutide compare to other weight loss drugs (e.g., semaglutide, tirzepatide)?
Retatrutide’s triple-agonist mechanism provides greater weight loss efficacy compared to GLP-1 receptor agonists and dual agonists such as tirzepatide, as confirmed by several network meta-analyses and head-to-head trials. However, the difference is less pronounced in individuals with type 2 diabetes.
- Meta-analyses rank retatrutide (8 mg and 12 mg) as the most effective available agent for weight loss, followed by tirzepatide and semaglutide 4 5 12.
- Direct comparisons show retatrutide leads to more substantial weight and waist circumference reductions than semaglutide, liraglutide, and tirzepatide, especially in people without diabetes 5 12.
- In type 2 diabetes populations, the absolute weight loss is reduced, but retatrutide still outperforms other agents 2 5.
- Dual and triple agonists generally show greater efficacy than GLP-1 mono-agonists across studies 5 12.
What are the main safety considerations and adverse events?
The safety profile of retatrutide is similar to other GLP-1 receptor agonists and dual agonists, with gastrointestinal symptoms being the most frequent adverse events. Most events are mild to moderate and dose-related, but higher discontinuation rates are observed compared to placebo.
- Nausea, diarrhea, vomiting, and constipation are common, affecting up to 84% of participants in some studies 1 2 4 13.
- Discontinuation due to adverse events is more frequent with retatrutide and related drugs than with placebo, but serious adverse events and deaths are rare and not typically attributed to the study drug 1 2 4 5 12 13.
- The incidence and severity of adverse events tend to increase with higher doses 1 2 5 12.
- No significant increase in serious hypoglycemia or life-threatening events has been reported 2 5 13.
What broader health impacts (beyond weight loss) have been observed?
Beyond weight reduction, retatrutide and similar agents show promise in improving cardiometabolic risk factors and markers of metabolic health. Evidence suggests beneficial effects on blood pressure, lipid profiles, liver fat, and possibly other obesity-related conditions, although data on long-term outcomes are still limited.
- Studies report improvements in HbA1c, blood pressure, lipid parameters, and inflammation markers in populations treated with retatrutide 2 3 11 13.
- Trials in patients with metabolic liver disease show marked reductions in liver fat and improvements in insulin sensitivity 3.
- The potential for reducing cardiovascular events, osteoarthritis symptoms, and sleep apnea is being actively investigated 3 13.
- Long-term impact on chronic disease outcomes and mortality remains to be determined through ongoing trials 3 11.
Future Research Questions
While the TRIUMPH-2 study and related research provide strong evidence for the efficacy of retatrutide, several important questions remain. Future research should address long-term safety, effectiveness in diverse subpopulations, real-world adherence, and the drug's broader impact on obesity-related complications.
| Research Question | Relevance |
|---|---|
| What are the long-term cardiovascular outcomes of retatrutide in people with obesity and type 2 diabetes? | Cardiovascular benefits are suggested by improved risk markers, but definitive outcome data are lacking. Large, long-term trials are needed to assess effects on major cardiovascular events 3 11. |
| How does retatrutide compare to tirzepatide for weight loss and metabolic improvement in type 2 diabetes? | Head-to-head data are limited, especially in diabetic populations where efficacy gaps may be narrower; direct comparative trials could inform treatment choice 5 12. |
| What factors predict individual response or adverse events with retatrutide treatment? | Identifying predictors of efficacy and tolerability could enable personalized treatment and minimize discontinuation due to side effects 12 13. |
| Does retatrutide improve other obesity-related complications, such as sleep apnea or osteoarthritis? | Trials are ongoing in these areas, but data are preliminary; broader health impacts could expand the drug’s clinical utility 3 13. |
| What are the real-world adherence and effectiveness of retatrutide outside clinical trials? | Clinical trial populations are highly selected; real-world studies are needed to assess adherence, effectiveness, and safety in broader patient groups 12 13. |
This article provides an evidence-based summary of the latest phase 3 trial of retatrutide, contextualized within the broader scientific literature on obesity pharmacotherapy. The available data support retatrutide’s potential as a highly effective weight loss and metabolic agent, while also highlighting the need for further research to clarify long-term outcomes, comparative effectiveness, and broader health impacts.